Results 61 to 70 of about 36,198 (299)

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source

Evaluation of Cardiorenal Metabolic Syndrome in Patients with Heart Failure with Preserved Ejection Fraction. How Aware Are We?

Sakarya Tıp Dergisi
Aim: Despite the prevalence of cardiorenal metabolic diseases (CRMD) in heart failure with preserved ejection fraction (HFpEF) patients and their significant complications, they are thought to be under-recognized and under-screened.
Dilan Damla Ozturk, Fatih Necip Arıcı, Cigdem Erhan, Bektaş Işık, Mehmet Can Erişen, Berçem Berent Kaya, Ugur Can Izlimek, Cahit Dincer, Ahmet Gazi Mustan, Çisem Yılmaz, Tayyibe Saler, Hilmi Erdem Sümbül, Erdinc Gulumsek, Hüseyin Ali Öztürk   +13 more
doaj   +1 more source

Exercise training ameliorates myocardial phenotypes in heart failure with preserved ejection fraction by changing N6-methyladenosine modification in mice model

Frontiers in Cell and Developmental Biology, 2022
Heart failure with preserved ejection fraction (HFpEF) shows complicated and not clearly defined etiology and pathogenesis. Although no pharmacotherapeutics have improved the survival rate in HFpEF, exercise training has become an efficient intervention ...
Kai Liu, Kai Liu, Kai Liu, Wenhao Ju, Wenhao Ju, Wenhao Ju, Shengrong Ouyang, Shengrong Ouyang, Zhuo Liu, Zhuo Liu, Feng He, Feng He, Jingyi hao, Hongyan Guan, Hongyan Guan, Jianxin Wu, Jianxin Wu, Jianxin Wu, Jianxin Wu, Jianxin Wu   +19 more
doaj   +1 more source

Heart failure with preserved ejection fraction. [PDF]

, 2012
Heart failure with preserved ejection fraction (HFpEF) has recently emerged as a major cause of cardiovascular morbidity and mortality. Contrary to initial beliefs, HFpEF is now known to be as common as heart failure with reduced ejection fraction (HFrEF)
ElGuindy, A, Yacoub, MH
core   +1 more source

Aortic flow is abnormal in HFpEF

Wellcome Open Research, 2023
Aims Turbulent aortic flow makes the cardiovascular system less effective. It remains unknown if patients with heart failure with preserved ejection fraction (HFpEF) have disturbed aortic flow. This study sought to investigate advanced markers of aortic flow disturbances in HFpEF.
Mehmood, Z., Assadi, H., Li, R., Kasmai, B., Matthews, G., Grafton-Clarke, C., Sanz-Cepero, A., Zhao, X., Zhong, L., Aung, N., Skinner, K., Hadinnapola, C., Swoboda, P., Swift, A.J., Vassiliou, V.S., Miller, C., van der Geest, R.J., Peterson, S., Garg, P.   +18 more
openaire   +6 more sources

Incident heart failure: comparing management and outcome in primary and hospital settings in Western Sweden 2008–2017

ESC Heart Failure, Volume 12, Issue 2, Page 832-838, April 2025.
Abstract Aim Heart failure (HF) is a highly prevalent condition managed in both primary care (PC) and hospital care (HC)‐based settings. HF patients managed in these two settings may differ in their demography, comorbidities and outcomes, so we aimed to compare the patient management in PC and HC in the Västra Götaland Region (VGR) in Sweden.
Xiaojing Chen, Aldina Pivodic, Maria Schaufelberger, Annika Rosengren, Michael Fu   +4 more
wiley   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Echocardiographic and Clinical Correlates of Ejection Fraction Among 2000 Patients with Heart Failure in Western Saudi Arabia

International Journal of General Medicine, 2020
Ahmed Hussein Subki,1 Mohammed Ali Almalki,2 Nadeem Shafique Butt,3 Mohammed Saad Alsallum,4 Hatim Mashan Almutairi,5 Hazim Abdulkarim Khatib,6 Abdulrahman Mousa Alzahrani,6 Abdullah Salem Babaker,6 Firas Abdulrahman Addas,6 Abdullah Abdulfattah Mashat,7
Subki AH, Almalki MA, Butt NS, Alsallum MS, Almutairi HM, Khatib HA, Alzahrani AM, Babaker AS, Addas FA, Mashat AA, Jad AY, Zafar ZA, Nogali BW, Alghamdi AA, Alghamdi NA, Dakhakhni MF, Asaad OT, Alghalayini KW   +17 more
doaj  

Impact of type 2 diabetes mellitus on heart failure with preserved ejection fraction depending on the presence of atrial fibrillation

Mìžnarodnij Endokrinologìčnij Žurnal, 2023
Background. Cardiovascular diseases, including heart failure (HF) and heart failure with preserved ejection fraction (HFpEF), pose a global health challenge.
N.M. Kulaiets, V.M. Kulaiets, O.O. Tkachuk-Hryhorchuk, N.B. Nyshchuk-Oliinyk   +3 more
doaj   +1 more source

Response to pulmonary arterial hypertension drug therapies in patients with pulmonary arterial hypertension and cardiovascular risk factors. [PDF]

, 2014
The age at diagnosis of pulmonary arterial hypertension (PAH) and the prevalence of cardiovascular (CV) risk factors are increasing. We sought to determine whether the response to drug therapy was influenced by CV risk factors in PAH patients. We studied
Charalampopoulos, A, Connolly, SB, Davies, RJ, Gibbs, JS, Gin-Sing, W, Grapsa, J, Howard, LS, Nihoyannopoulos, P, Tzoulaki, I, Wilkins, MR   +9 more
core   +1 more source